Sign in

    Billy

    Vice President and Equity Research Analyst at JPMorgan Chase & Co.

    Billy Chen is a Vice President and Equity Research Analyst at JPMorgan Chase & Co., specializing in healthcare and biotechnology sectors with in-depth coverage of companies such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals. Known for his analytical precision, he maintains a strong performance track record, with a historically high recommendation accuracy and above-average returns as noted by analyst ranking platforms. Billy began his financial services career at Morgan Stanley in 2013, progressing through various analyst roles before joining JPMorgan in 2018. He is FINRA-registered with Series 7 and Series 63 licenses, recognized for his robust industry insights and incisive equity recommendations.

    Billy's questions to Vir Biotechnology (VIR) leadership

    Billy's questions to Vir Biotechnology (VIR) leadership • Q4 2024

    Question

    Billy, on behalf of JPMorgan, asked if Vir plans to pursue an every-three-week dosing schedule for its EGFR T-cell engager, VIR-5525, similar to its other two T-cell engager programs.

    Answer

    CEO Dr. Marianne De Backer confirmed that Vir is exploring both weekly and every-three-week dosing for the HER2 and PSMA programs and plans to do the same for the EGFR program. She noted that the pharmacokinetic half-life data from the existing clinical programs is encouraging for less frequent dosing schedules.

    Ask Fintool Equity Research AI